DEF: TELA Bio 2026 Proxy: Board Refresh and Equity Plan Update

TELA Bio, Inc. announces its 2026 Annual Meeting of Stockholders, featuring a significant board refreshment and a proposal to increase equity incentive plan shares.

Summary

• The 2026 Annual Meeting of Stockholders is scheduled for June 9, 2026, in a virtual-only format.
• Key proposals include the election of three Class I directors, ratification of KPMG LLP as the independent auditor, an advisory vote on executive compensation, and an amendment to the 2019 Equity Incentive Plan to increase authorized shares by 3,500,000.
• The company reported record revenue of $20.9 million in Q4 2025 and $80.3 million for the full year 2025, representing 18% and 16% year-over-year growth, respectively.
• A significant board refreshment is underway, with four directors resigning and four new directors being appointed or nominated.
• The company recently closed a $70 million credit facility with Perceptive Advisors and an $11.6 million net proceeds equity offering.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive filing; while the company is showing solid revenue growth and has successfully raised capital, the ongoing net losses and shareholder dilution from the equity plan increase temper the outlook.

Positives

• Record revenue performance in 2025 with $80.3 million in total revenue, up 16% from 2024.
• Successful commercial launch of larger sized OviTex PRS for plastic and reconstructive surgery.
• Strengthened balance sheet through a $70 million credit facility and an $11.6 million equity offering.
• Proactive board refreshment to align leadership with long-term strategic priorities.

Negatives

• The company continues to report net losses, with a net loss of $38.8 million in 2025.
• The proposed increase of 3,500,000 shares in the equity incentive plan will result in further dilution to existing shareholders.
• Director attendance at committee meetings was mixed, with one director attending only 50% of meetings.

Risks

• Continued reliance on equity-based compensation to attract and retain talent, which may lead to further dilution.
• Potential for insufficient votes to approve the equity plan amendment, necessitating an adjournment of the meeting.
• Market volatility impacting the value of equity awards and the company's ability to raise capital.
• Dependence on achieving specific net revenue thresholds to access the remaining $10 million of the credit facility.

Future Outlook

The company intends to continue its commercial expansion of OviTex PRS and focus on long-term strategic priorities, supported by the newly refreshed Board and the proposed increase in equity incentive capacity.

Management Comments

• The Board believes that the virtual meeting format enables stockholders to attend and participate from any location around the world at no cost.
• The board refreshment described herein is expected to be completed substantially concurrently with the conclusion of the Annual Meeting.
• The Board and Company believes that the refreshment described herein reflects the Company's dedication to evolving Board leadership in a manner that is aligned with the long-term interests of the Company and its stockholders.

Industry Context

StockSavvy.ai notes that TELA Bio is navigating a challenging environment for medical device companies, characterized by the need for continuous innovation and capital-intensive growth. The board refreshment and equity plan expansion are common strategies for companies in the commercialization phase to attract high-level talent and maintain competitive positioning.

Comparison to Industry Standards

• The company's revenue growth of 16% is consistent with mid-stage medical technology companies scaling commercial operations.
• The use of a virtual-only meeting format is increasingly common among U.S. public companies to reduce costs and environmental impact.
• The board structure and committee independence align with standard corporate governance practices for Nasdaq-listed companies.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• Sale of distribution rights for NIVIS Fibrillar Collagen Pack to MiMedx Group, Inc. in March 2024 for $5.0 million plus future payments.
• Participation of executive officers in the October 2024 public offering.

Stakeholder Impact

• Shareholders will face dilution if the equity plan amendment is approved.
• Employees may benefit from the expanded equity incentive pool for retention and motivation.
• Creditors are impacted by the $70 million credit facility.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on June 9, 2026.
• Execute the board transition immediately following the Annual Meeting.
• Implement the 2019 Plan Amendment if approved by stockholders.

Key Dates

Recommendation

The company is showing strong revenue growth, but the persistent net losses and the need for ongoing capital raises and equity dilution suggest a cautious 'hold' approach until the company demonstrates a clearer path to profitability.

Keywords

TELA Bio, Proxy Statement, Medical Technology, Equity Incentive Plan, Board Refreshment, Corporate Governance, Surgical Reconstruction